EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access

A Comparison Study of Olmesartan and Valsartan Effects on Myocardial Metabolism in Patients With Dilated Cardiomyopathy: the OVOID Trial

Sangyong Jo iD, Kyungil Park iD, Jae Hyuk Choi, Chang-Bae Sohn, Jeonghwan Kim, Yong-Seop Kwon, Su Hong Kim iD, Tae-Ho Park

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.125.041406 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Sangyong Jo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Regional Cardiocerebrovascular Center Dong-A University Hospital Busan Republic of Korea. Hauptthemen laut MEDLINE: Valsartan, Cardiomyopathy, Dilated, Imidazoles, Tetrazoles. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Myocardial metabolism plays an important role in maintaining cardiac function. Patients with dilated cardiomyopathy exhibit alterations in myocardial metabolism characterized by increased myocardial glucose metabolism. This study aimed to evaluate effects on myocardial metabolism of the angiotensin II receptor blockers olmesartan and valsartan in patients with dilated cardiomyopathy. We hypothesized that olmesartan, owing to its stronger and longer‐lasting angiotensin II receptor blockade, would lead to a greater reduction in myocardial glucose metabolism compared with valsartan.

Methods

OVOID (A Comparison Study of Olmesartan and Valsartan Effects on Myocardial Metabolism in Patients With Dilated Cardiomyopathy) was a multicenter, randomized controlled trial involving 44 patients with New York Heart Association classes II through IV dilated cardiomyopathy. Participants were randomized 1:1 to receive olmesartan (20 mg once daily) or valsartan (160 mg twice daily) for 6 months, in addition to standard care. The primary outcome was myocardial glucose metabolism measured by standardized uptake value ratio at 6 months after treatment. To measure standardized uptake value ratio, 18 F‐fluoro‐2‐deoxyglucose cardiac positron emission tomography was performed at baseline and 6 months after receiving the study agent.

Results

Baseline clinical characteristics and standardized uptake value ratio were not significantly different between the 2 groups. The average left ventricular ejection fraction was 25.1%±7.8% at baseline, with significant improvement in both groups after 6 months, though with no difference between them. At 6 months, the standardized uptake value ratio value was significantly lower in the olmesartan group than that in the valsartan (3.76±2.00 versus 5.76±3.10; P =0.01).

Conclusions

Six months of olmesartan therapy significantly decreased myocardial glucose metabolism in dilated cardiomyopathy patients compared with valsartan therapy for 6 months. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04174456.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ValsartanCardiomyopathy, DilatedImidazolesTetrazolesAngiotensin II Type 1 Receptor BlockersMyocardiumEnergy MetabolismHumansMaleFemaleMiddle AgedTreatment OutcomePositron-Emission TomographyAgedAdultFluorodeoxyglucose F18GlucoseTime Factors

Stichwörter der Autor:innen

myocardial metabolismolmesartanpositron emission tomographyvalsartan

Substanzen

ValsartanolmesartanImidazolesTetrazolesAngiotensin II Type 1 Receptor BlockersFluorodeoxyglucose F18Glucose

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, Regional Cardiocerebrovascular Center Dong-A University Hospital Busan Republic of Korea.
  • Dong-A University College of Medicine Busan Republic of Korea.
  • Gimhaebokum Hospital Gimhae Republic of Korea.
  • Ulsan Medical Center Ulsan Republic of Korea.
  • Dong-eui Hospital Busan Republic of Korea.
  • Busan St.Mary's Hospital Busan Republic of Korea.

ORCID-Profile: Sangyong Jo, Kyungil Park, Su Hong Kim

Zitieren

APA

Jo, S., Park, K., Choi, J. H., Sohn, C. B., Kim, J., Kwon, Y. S., Kim, S. H., & Park, T. H. (2025). A Comparison Study of Olmesartan and Valsartan Effects on Myocardial Metabolism in Patients With Dilated Cardiomyopathy: the OVOID Trial. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.041406

Vancouver

Jo S, Park K, Choi JH, Sohn CB, Kim J, Kwon YS, et al. A Comparison Study of Olmesartan and Valsartan Effects on Myocardial Metabolism in Patients With Dilated Cardiomyopathy: the OVOID Trial. Journal of the American Heart Association. 2025. doi:10.1161/jaha.125.041406

BibTeX
@article{Jo2025,
  author = {Jo, Sangyong and Park, Kyungil and Choi, Jae Hyuk and Sohn, Chang-Bae and Kim, Jeonghwan and Kwon, Yong-Seop and Kim, Su Hong and Park, Tae-Ho},
  title = {A Comparison Study of Olmesartan and Valsartan Effects on Myocardial Metabolism in Patients With Dilated Cardiomyopathy: the OVOID Trial},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.125.041406}
}
Kostenlos starten →